Investing.com -- Pfizer (NYSE: PFE ), the pharmaceutical giant, has decided to discontinue the global development and commercialization of its gene therapy product, Beqvez, used for treating hemophilia, according to a Thursday report by Nikkei . This was confirmed by a Pfizer representative on Thursday who stated that this was a business decision.

This move comes after Pfizer previously ceased its other similar treatment for the disorder in December.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.